NCT03020004 - Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

February 28, 2017

Conditions

Chronic Hepatitis C

Interventions

DRUG

Danoprevir

Danoprevir (DNV) 100mg tablet administered orally twice daily

DRUG

Ritonavir

Ritonavir 100mg tablet administered orally twice daily

DRUG

peginterferon alfa-2a

PegIFN subcutaneous injection at 180 mcg weekly

DRUG

Ribavirin (RBV)

Ribavirin (RBV)1000/1200 mg/day (bodyweight\<75/≥75 kg)